U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C18H17ClN2O2
Molecular Weight 328.793
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXAZOLAM

SMILES

CC1CN2CC(=O)NC3=C(C=C(Cl)C=C3)C2(O1)C4=CC=CC=C4

InChI

InChIKey=VCCZBYPHZRWKFY-UHFFFAOYSA-N
InChI=1S/C18H17ClN2O2/c1-12-10-21-11-17(22)20-16-8-7-14(19)9-15(16)18(21,23-12)13-5-3-2-4-6-13/h2-9,12H,10-11H2,1H3,(H,20,22)

HIDE SMILES / InChI

Molecular Formula C18H17ClN2O2
Molecular Weight 328.793
Charge 0
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1254

Oxazolam is a prodrug (precursor) for the benzodiazepine desmethyl-diazepam (nordazepam) and is itself a metabolic product of other benzodiazepines. It has anxiolytic, sedative, and anticonvulsant properties. It is a GABA-A receptor agonist. Oxazolam is marketed in Japan under the brand name Serenal. It is usually used to treat anxiety, tension, depression, and sleeping disorder in neurosis. It is used to treat somatic symptoms in psychosomatic disorders (gastrointestinal diseases, circulatory diseases, endocrine diseases, and autonomic dystonia), anxiety, tension, and depression. It is also used as a preanesthetic medication.

CNS Activity

Curator's Comment: Oxazolam showed no affinity toward benzodiazepine receptor, although it showed moderate in vivo activity. However, its metabolites were found to have both high affinity and in vivo activities. In the case of oxazolam, their metabolites may bind to receptor sites in the brain and then elicit pharmacological action.

Originator

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Serenal

Approved Use

Serenal is usually used to treat anxiety, tension, depression, and sleeping disorder in neurosis. It is used to treat somatic symptoms in psychosomatic disorders (gastrointestinal diseases, circulatory diseases, endocrine diseases, and autonomic dystonia), anxiety, tension, and depression. It is also used as a preanesthetic medication.
Primary
Serenal

Approved Use

Serenal is usually used to treat anxiety, tension, depression, and sleeping disorder in neurosis. It is used to treat somatic symptoms in psychosomatic disorders (gastrointestinal diseases, circulatory diseases, endocrine diseases, and autonomic dystonia), anxiety, tension, and depression. It is also used as a preanesthetic medication.
PubMed

PubMed

TitleDatePubMed
Comparative single-dose kinetics of oxazolam, prazepam, and clorazepate: three precursors of desmethyldiazepam.
1984 Oct
Patents

Sample Use Guides

General dosage regimen: For adults, take 1 to 2 tablets (10 to 20 mg of the active ingredient) at a time, 3 times daily. If you take the medicine as a preanesthetic medication, take 1 to 2 mg/kg of the active ingredient before going to bed or the surgery.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 18:02:04 GMT 2023
Edited
by admin
on Sat Dec 16 18:02:04 GMT 2023
Record UNII
1V2WI2NA1C
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OXAZOLAM
INN   MART.   WHO-DD  
INN  
Official Name English
TRANQUIT
Brand Name English
oxazolam [INN]
Common Name English
OXAZOLAM [MART.]
Common Name English
OXAZOLAM [MI]
Common Name English
HIALIZAN
Brand Name English
OXAZOLAM [JAN]
Common Name English
SERENAL
Brand Name English
Oxazolam [WHO-DD]
Common Name English
Classification Tree Code System Code
DEA NO. 2839
Created by admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
Code System Code Type Description
ChEMBL
CHEMBL2104805
Created by admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
PRIMARY
FDA UNII
1V2WI2NA1C
Created by admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
PRIMARY
WIKIPEDIA
OXAZOLAM
Created by admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
PRIMARY
NCI_THESAURUS
C166515
Created by admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
PRIMARY
CAS
24143-17-7
Created by admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
PRIMARY
EPA CompTox
DTXSID5023401
Created by admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
PRIMARY
MERCK INDEX
m8296
Created by admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
PRIMARY
MESH
C000425
Created by admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
PRIMARY
DRUG BANK
DB15491
Created by admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
PRIMARY
EVMPD
SUB09508MIG
Created by admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
PRIMARY
INN
3013
Created by admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
PRIMARY
DRUG CENTRAL
2016
Created by admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
PRIMARY
SMS_ID
100000083054
Created by admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
PRIMARY
PUBCHEM
4617
Created by admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
PRIMARY
ECHA (EC/EINECS)
246-032-0
Created by admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY